The impact of TP53 mutations and use of the TP53-mutation-reactivating agent APR-246 on metastatic castrate-sensitive prostate cancer.

被引：0
|
作者：
Hoang, Tung
Sutera, Philip
Nguyen, Triet
Chang, Jin Hee
Jagtap, Shreya
Song, Yang
Shetty, Amol
Chowdhury, Dipanwita
Chan, Aaron
Carrieri, Francesca Anna
Song, Daniel Y.
DeWeese, Theodore L.
Lafargue, Audrey
Van der Eecken, Kim
Ost, Fred Bunz Piet
Tran, Phuoc T.
Deek, Matthew
机构：
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[2] Johns Hopkins Univ, Baltimore, MD USA
[3] Univ Maryland, Baltimore, MD USA
[4] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[5] Johns Hopkins Univ, Dept Radiat Oncol & Mol Radiat Sci, Sch Med, Baltimore, MD USA
[6] Ghent Univ Hosp, Ghent, Belgium
[7] Univ Ghent, Ghent, Belgium
[8] Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17077
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Prognostic value of tumour suppression genes (TP53, PTEN, Rb) in metastatic hormone sensitive prostate cancer
    Gonzalez Velez, M. G.
    Kosiorek, H. E.
    Egan, J.
    Bryce, A. H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [42] Are mutations of the TP53 tumour suppressor gene risk factors for prostate cancer formation?
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (03) : 183 - 183
  • [43] Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
    Åsa Fransson
    Daria Glaessgen
    Jessica Alfredsson
    Klas G. Wiman
    Svetlana Bajalica-Lagercrantz
    Nina Mohell
    Journal of Ovarian Research, 9
  • [44] Association of TP53 mutation with decreased prevalence of MSI-high, RAS and PI3KCA mutations in metastatic colorectal cancer.
    Pan, Minggui
    Jiang, Chen
    Tse, Pamela
    Solorzano-Pinto, Aleyda V.
    Chung, Elaine
    Truong, Thach-Giao
    Arora, Amit
    Sundaresan, Tilak Kumar
    Suga, Jennifer Marie Marie
    Habel, Laurel A.
    Thomas, Sachdev P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation
    Teruyuki Kobayashi
    Tomoki Makino
    Kotaro Yamashita
    Takuro Saito
    Koji Tanaka
    Tsuyoshi Takahashi
    Yukinori Kurokawa
    Makoto Yamasaki
    Kiyokazu Nakajima
    Eiichi Morii
    Hidetoshi Eguchi
    Yuichiro Doki
    British Journal of Cancer, 2021, 125 : 1523 - 1532
  • [46] APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation
    Kobayashi, Teruyuki
    Makino, Tomoki
    Yamashita, Kotaro
    Saito, Takuro
    Tanaka, Koji
    Takahashi, Tsuyoshi
    Kurokawa, Yukinori
    Yamasaki, Makoto
    Nakajima, Kiyokazu
    Morii, Eiichi
    Eguchi, Hidetoshi
    Doki, Yuichiro
    BRITISH JOURNAL OF CANCER, 2021, 125 (11) : 1523 - 1532
  • [47] Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
    Fransson, Asa
    Glaessgen, Daria
    Alfredsson, Jessica
    Wiman, Klas G.
    Bajalica-Lagercrantz, Svetlana
    Mohell, Nina
    JOURNAL OF OVARIAN RESEARCH, 2016, 9
  • [48] Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
    Sallman, David A.
    DeZern, Amy E.
    Garcia-Manero, Guillermo
    Steensma, David P.
    Roboz, Gail J.
    Sekeres, Mikkael A.
    Cluzeau, Thomas
    Sweet, Kendra L.
    McLemore, Amy F.
    McGraw, Kathy
    Puskas, John
    Zhang, Ling
    Yao, Jiqiang
    Mo, Qianxing
    Nardelli, Lisa
    Al Ali, Najla
    Padron, Eric
    Korbel, Greg
    Attar, Eyal C.
    Kantarjian, Hagop M.
    Lancet, Jeffrey E.
    Fenaux, Pierre
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2019, 134
  • [49] TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes
    A Petitjean
    M I W Achatz
    A L Borresen-Dale
    P Hainaut
    M Olivier
    Oncogene, 2007, 26 : 2157 - 2165
  • [50] Mutant KRAS and TP53 with high mutation allelic frequency in ctDNA as poor outcome predictors in metastatic pancreatic cancer.
    Guan, Shasha
    Shi, Yan
    Han, Quanli
    Li, Jie
    Lv, Yao
    Yan, Huan
    Han, Lu
    Chen, Yang
    Qian, Niansong
    Wang, Zhikuan
    Shi, Huaiyin
    Dai, Guanghai
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345